| scholarly article | Q13442814 |
| P50 | author | Tracey M Hinton | Q56816676 |
| Nicholas P Reynolds | Q59543481 | ||
| P2093 | author name string | Megan Dearnley | |
| P2860 | cites work | Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis. | Q23047571 |
| The nuclear RNase III Drosha initiates microRNA processing | Q24295234 | ||
| Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs | Q24302072 | ||
| Identification of mammalian microRNA host genes and transcription units | Q24562298 | ||
| The evolution of RNAi as a defence against viruses and transposable elements | Q24651901 | ||
| On the origin and functions of RNA-mediated silencing: from protists to man | Q24657546 | ||
| Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia | Q24696012 | ||
| Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside | Q26741449 | ||
| Approved Antiviral Drugs over the Past 50 Years | Q27755387 | ||
| Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans | Q27860867 | ||
| A system for stable expression of short interfering RNAs in mammalian cells | Q27860875 | ||
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| Fomivirsen: clinical pharmacology and potential drug interactions | Q28215867 | ||
| Silencing or stimulation? siRNA delivery and the immune system | Q28262321 | ||
| Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study | Q28269717 | ||
| RNAi, microRNAs, and human disease | Q28273238 | ||
| Second-generation shRNA libraries covering the mouse and human genomes | Q28275183 | ||
| Molecular mechanisms of RNA interference | Q28290306 | ||
| The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis | Q28297566 | ||
| par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed | Q28301842 | ||
| Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool | Q28385526 | ||
| NLRP3 inflammasome activation induced by engineered nanomaterials | Q28387817 | ||
| Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity | Q28388552 | ||
| Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine | Q28390007 | ||
| Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial | Q28551448 | ||
| Conventional transmission electron microscopy | Q28659693 | ||
| Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice | Q29036869 | ||
| Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration | Q29615596 | ||
| MicroRNA Regulation of RNA Virus Replication and Pathogenesis | Q39042688 | ||
| Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy | Q39066848 | ||
| MicroRNA 155 and viral-induced neuroinflammation. | Q39111001 | ||
| Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery | Q39231430 | ||
| Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque | Q39362979 | ||
| Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. | Q39432685 | ||
| Comparison of four different particle sizing methods for siRNA polyplex characterization | Q39534238 | ||
| Tolerance for mutations and chemical modifications in a siRNA. | Q39698017 | ||
| Noninvasive visualization of RNA delivery with 99mTc-radiolabeled small-interference RNA in tumor xenografts | Q39702371 | ||
| Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant | Q39886596 | ||
| Inhibition of chicken anaemia virus replication using multiple short-hairpin RNAs. | Q39964715 | ||
| Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates | Q39973841 | ||
| Large-scale production of dsRNA and siRNA pools for RNA interference utilizing bacteriophage phi6 RNA-dependent RNA polymerase | Q40181185 | ||
| Suppression of bovine viral diarrhea virus replication by small interfering RNA and short hairpin RNA-mediated RNA interference. | Q40217867 | ||
| Silencing of HIV-1 with RNA interference: a multiple shRNA approach | Q40234514 | ||
| Rotavirus gene silencing by small interfering RNAs | Q40429464 | ||
| Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity. | Q40552724 | ||
| Demonstration of d-Octaarginine-Linked Polymers as Promising Adjuvants for Mucosal Vaccination through Influenza Virus Challenge | Q40598043 | ||
| Outbreak of H5N2 highly pathogenic avian Influenza A virus infection in two commercial layer facilities: lesions and viral antigen distribution | Q40611277 | ||
| Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis | Q40632272 | ||
| Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference | Q40695522 | ||
| Nanoparticle suspensions enclosed in methylcellulose: a new approach for quantifying nanoparticles in transmission electron microscopy. | Q40770981 | ||
| Biodegradable Film for the Targeted Delivery of siRNA-Loaded Nanoparticles to Vaginal Immune Cells. | Q40811530 | ||
| ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients | Q40959333 | ||
| siRNA Selection Server: an automated siRNA oligonucleotide prediction server | Q41010535 | ||
| Concomitant Raman spectroscopy and dynamic light scattering for characterization of therapeutic proteins at high concentrations | Q41727065 | ||
| Emerging viral diseases: confronting threats with new technologies | Q41744062 | ||
| siRNA function in RNAi: a chemical modification analysis | Q42044356 | ||
| RNA interference with measles virus N, P, and L mRNAs efficiently prevents and with matrix protein mRNA enhances viral transcription | Q42153804 | ||
| Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union | Q42516930 | ||
| ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization | Q42532362 | ||
| Oncolytic Treatment for Cancer Recommended for Approval | Q42553424 | ||
| Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt | Q42760569 | ||
| The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. | Q42829655 | ||
| Production of antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle. | Q43747902 | ||
| Development of vaccine adjuvants using polymeric nanoparticles and their potential applications for anti-HIV vaccine | Q44170395 | ||
| Quantitative mapping of the elastic modulus of soft materials with HarmoniX and PeakForce QNM AFM modes | Q44445707 | ||
| RNA interference in mammalian cells by chemically-modified RNA. | Q44496696 | ||
| RNA interference therapy in lung transplant patients infected with respiratory syncytial virus | Q45372948 | ||
| Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). | Q45397417 | ||
| Short interfering RNA-directed inhibition of hepatitis B virus replication | Q45723559 | ||
| The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. | Q45977543 | ||
| Targeted quantum dot conjugates for siRNA delivery | Q46077915 | ||
| Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs | Q46081080 | ||
| Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. | Q46188888 | ||
| Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. | Q48530108 | ||
| Comparing Gene Silencing and Physiochemical Properties in siRNA Bound Cationic Star-Polymer Complexes. | Q48590273 | ||
| The effect of RAFT-derived cationic block copolymer structure on gene silencing efficiency. | Q50493056 | ||
| Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. | Q51046784 | ||
| Ecological dynamics of emerging bat virus spillover. | Q51160081 | ||
| A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. | Q51290726 | ||
| Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance. | Q51337864 | ||
| Probing the influence of stereoelectronic effects on the biophysical properties of oligonucleotides: comprehensive analysis of the RNA affinity, nuclease resistance, and crystal structure of ten 2'-O-ribonucleic acid modifications. | Q53854132 | ||
| Tunable Rigidity of (Polymeric Core)-(Lipid Shell) Nanoparticles for Regulated Cellular Uptake | Q57238665 | ||
| Corona-Stabilized Interpolyelectrolyte Complexes of SiRNA with Nonimmunogenic, Hydrophilic/Cationic Block Copolymers Prepared by Aqueous RAFT Polymerization†| Q57368272 | ||
| Cellular Uptake of Elastic Nanoparticles | Q60134097 | ||
| RNA interference targeting Fas protects mice from fulminant hepatitis | Q78961966 | ||
| Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants | Q80279635 | ||
| Small silencing RNAs | Q81316229 | ||
| Industrial-scale manufacturing of a possible oligonucleotide cargo CPP-based drug | Q82324685 | ||
| Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles | Q84295405 | ||
| Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants | Q29615635 | ||
| A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models | Q30379545 | ||
| Entrapment of H1N1 Influenza Virus Derived Conserved Peptides in PLGA Nanoparticles Enhances T Cell Response and Vaccine Efficacy in Pigs. | Q30387075 | ||
| Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. | Q30837863 | ||
| The use of environmental scanning electron microscopy for imaging wet and insulating materials | Q33187977 | ||
| Reactive oxygen species (ROS) induced cytokine production and cytotoxicity of PAMAM dendrimers in J774A.1 cells | Q33565097 | ||
| Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency | Q33567468 | ||
| Analyzing subvisible particles in protein drug products: a comparison of dynamic light scattering (DLS) and resonant mass measurement (RMM) | Q33574160 | ||
| Cationic poly(amidoamine) dendrimer induces lysosomal apoptotic pathway at therapeutically relevant concentrations | Q33585496 | ||
| Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment | Q33676644 | ||
| Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles | Q33687357 | ||
| Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization. | Q33877287 | ||
| A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus | Q33928650 | ||
| Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia | Q34040047 | ||
| How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells | Q34243293 | ||
| Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives | Q34415371 | ||
| Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates | Q34473079 | ||
| Antisense approach to inflammatory bowel disease: prospects and challenges | Q34473572 | ||
| Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation | Q34473856 | ||
| Inhibition of influenza virus production in virus-infected mice by RNA interference | Q34514513 | ||
| Protection against lethal influenza virus challenge by RNA interference in vivo. | Q34514565 | ||
| Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways | Q34530552 | ||
| State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. | Q34664690 | ||
| Potent inhibition of Hendra virus infection via RNA interference and poly I:C immune activation | Q34731475 | ||
| Biological applications of dendrimers | Q35019346 | ||
| An optimized microRNA backbone for effective single-copy RNAi | Q35065928 | ||
| Towards an understanding of the adjuvant action of aluminium | Q35138579 | ||
| Long (27-nucleotides) small inhibitory RNAs targeting E6 protein eradicate effectively the cervical cancer cells harboring human papilloma virus | Q35649376 | ||
| Control of nonsegmented negative-strand RNA virus replication by siRNA. | Q35739895 | ||
| Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot | Q35890093 | ||
| Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes | Q35928850 | ||
| RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients | Q36414524 | ||
| Airway CD8(+) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity | Q36499684 | ||
| Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection | Q36528415 | ||
| Toxicity of cationic lipids and cationic polymers in gene delivery | Q36532318 | ||
| Vaccine delivery using nanoparticles. | Q36712817 | ||
| OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics | Q36749348 | ||
| Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA | Q36815470 | ||
| The effect of particle design on cellular internalization pathways | Q36954579 | ||
| Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose | Q37126611 | ||
| Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy | Q37319940 | ||
| RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy | Q37333053 | ||
| Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial | Q37385677 | ||
| Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants | Q37481839 | ||
| Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals | Q37694413 | ||
| High-speed atomic force microscopy coming of age. | Q37976186 | ||
| Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases | Q38152851 | ||
| Lipid-based nanoparticles in the systemic delivery of siRNA. | Q38172634 | ||
| Lipid nanoparticles for short interfering RNA delivery | Q38269558 | ||
| Anti-HIV-1 activity of low molecular weight sulfated chitooligosaccharides. | Q38346824 | ||
| Retroviral delivery of RNA interference against Marek's disease virus in vivo | Q38434809 | ||
| Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. | Q38541054 | ||
| The Functions of MicroRNAs: mRNA Decay and Translational Repression | Q38599455 | ||
| Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron | Q38621943 | ||
| Clinical experiences with systemically administered siRNA-based therapeutics in cancer | Q38633261 | ||
| Inhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools. | Q38770194 | ||
| Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach | Q38777152 | ||
| Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))-poly(ethylene glycol) nanotechnology as a model: An industrial viewpoint | Q38824481 | ||
| Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing | Q38860419 | ||
| DLS and zeta potential - What they are and what they are not? | Q38864269 | ||
| Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy. | Q38871344 | ||
| Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting | Q38906057 | ||
| Recent progress in nanomaterials for gene delivery applications | Q38915104 | ||
| Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles | Q38933961 | ||
| The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery. | Q38934039 | ||
| Biodegradable nano-polymers as delivery vehicles for therapeutic small non-coding ribonucleic acids. | Q39019156 | ||
| Artificial microRNAs as antiviral strategy to FMDV: structural implications of target selection | Q39035918 | ||
| Inhibition of influenza virus in vivo by siRNA delivered using ABA triblock copolymer synthesized by reversible addition-fragmentation chain-transfer polymerization. | Q39040866 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 38 | |
| P577 | publication date | 2017-03-21 | |
| P1433 | published in | Topics in Current Chemistry | Q2443282 |
| P1476 | title | Polymers in the Delivery of siRNA for the Treatment of Virus Infections | |
| P478 | volume | 375 |
Search more.